Dermata Therapeutics, Inc. (DRMAW)

US — Healthcare Sector
Peers: CDIOW  DRMA  KTTAW  NLSPW 

Automate Your Wheel Strategy on DRMAW

With Tiblio's Option Bot, you can configure your own wheel strategy including DRMAW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DRMAW
  • Rev/Share 0.0
  • Book/Share 1.4164
  • PB 0.4588
  • Debt/Equity 0.0
  • CurrentRatio 6.9657
  • ROIC -1.7908

 

  • MktCap 4144501.0
  • FreeCF/Share -2.0161
  • PFCF -0.3988
  • PE -0.2924
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -2.7082

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Dermata Therapeutics, Inc. (DRMAW)

  • IPO Date 2021-08-13
  • Website http://www.dermatarx.com
  • Industry Biotechnology
  • CEO Gerald T. Proehl
  • Employees 8
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.